REMARKS

This is a Divisional application of application Serial No. 09/934,874.

Claim 1 in this Divisional application includes features from original claim 1 in parent application Serial No. 09/934,874 and from page 23, lines 1 to 4 of the present specification.

Claims 2 and 14 in this Divisional application include features of original claim 2 in parent application Serial No. 09/934,874.

Claims 3 and 15 in this Divisional application are supported by the second paragraph on page 7 of the present specification.

Claims 4 to 6 in this Divisional application are supported by Table 1 on page 37 of the present specification.

Claims 7 to 12 and 16 to 18 in this Divisional application are supported on page 23, lines 1 to 4 of the present specification.

Claim 13 in this Divisional application includes features from original claim 1 in parent application Serial No. 09/934,874.

Submitted concomitantly herewith is a DECLARATION UNDER 37 CFR 1.132 of Kazuyoshi MASAKI dated September 29, 2003. The results of the experiments in the enclosed MASAKI DECLARATION are summarized in the Table on page 4 of the MASAKI DECLARATION, which is reproduced hereinbelow:

Table Cytotoxicity against Cancer Cells: IC_{50} (μg/mL)

	SQAG 1	SQAG 2	SQAG 3
HeLa	>100	49	18
T24	>100	33	16
MCF-7	59	17	6
SKG-IIIb	49	13	4
HO-1-N-1	76	30	8
MIA PaCa-2	59	13	6
HUH-6 Clone 5	86	14	7
A-172	48	27	6
HT-1080	30	21	6
Mewo	86	15	4
U937	60	12	4
MOLT-4	64	23	7

The results in the above Table demonstrate that compounds SQAG 1, SQAG 2, and SQAG 3 according to the present invention provide unexpectedly good cytotoxicity against the cancer cells tested.

The compounds SQAG1, SQAG2 and SQAG3 are set forth in Table 1 on page 37 of the specification.

The following Table shows the relationship between the cells tested in the enclosed MASAKI DECLARATION and the types of cancers described on pages 22 to 23 of the specification.

Cell name		Correspondence to the types of cancer described on page 22, line 25 to page 23, line 4
HeLa	Human cervical adenocarcinoma cells	adenocarcinoma
T24	Human transitional cell carcinoma; urinary bladder cancer cells (malignant epithelioma)	epithelioma
MCF-7	Human mammary gland adenocarcinoma cells	adenocarcinoma
SKG-IIIb	Human squamous cell carcinoma; uterine cervix cancer cells	epithelioma
HO-1-N-1	Human squamous cell carcinoma; oral cancer cells	epithelioma
MIA PaCa-2	Human pancreatic adenocarcinoma cells	adenocarcinoma
HUH-6 Clone 5	Human hepatocellular carcinoma cells (malignant epithelioma)	epithelioma
A-172	Human glioblastoma cells (gliomatosis)	glioma
HT-1080	Human fibrosarcoma cells (sarcoma)	sarcoma
Mewo	Human melanoma cells	melanoma
U937	Human lymphoma cells	lymphoma
MOLT-4	Leukemia cells	leukemia

Respectfully submitted,

RICHARD S. BARTH
REG. NO. 28,180

FRISHAUF, HOLTZ, GOODMAN & CHICK, P.C.
767 THIRD AVENUE - 25TH FLOOR
NEW YORK, NEW YORK 10017-2023
Tel. Nos. (212) 319-4900
(212) 319-4551/Ext. 219
Fax No. (212) 319-5101
E-Mail Address: BARTH@FHGC-LAW.COM
RSB/ddf

Enc.: DECLARATION UNDER 37 CFR 1.132 of Kazuyoshi MASAKI
dated September 29, 2003